Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000361 · ClinicalTrials.gov registry record · Phase 3
Autoimmunity in Inner Ear Disease
A Phase 3 study, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).
- Terminated
- Registry status
- Phase 3
- Development phase
NCT00000361 is a Phase 3 study that was terminated before completion, run by National Institute on Deafness and Other Communication Disorders (NIDCD).
The verdict
NCT00000361, a Phase 3 study, was terminated before completion, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).
- TERMINATED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this study is to determine whether prednisone, methotrexate, and cyclophosphamide are effective in the treatment of rapidly progressive sensorineural hearing loss in both ears. This condition is called autoimmune inner ear disease (AIED), because it is thought that the hearing loss is triggered by an autoimmune process. Treatment attempts to suppress or control this process with powerful anti-inflammatory drugs. This is a Phase III, outpatient study. All study participants will be assigned to one of four different groups testing the experimental use of drugs. The study is scheduled to run for 18 months, with a minimum of 11 visits per participant.
Interventions
- DRUG Methotrexate
- DRUG Corticosteroids
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-03 |
| Est. Completion | 2002-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000361
The ClinicalTrials.gov registry entry for NCT00000361 describes a study currently listed as terminated, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute on Deafness and Other Communication Disorders (NIDCD), which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Methotrexate is the first listed.
NCT00000361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000361 about?
NCT00000361 is a clinical study titled "Autoimmunity in Inner Ear Disease". The purpose of this study is to determine whether prednisone, methotrexate, and cyclophosphamide are effective in the treatment of rapidly progressive sensorineural hearing loss in both ears. This condition is called autoimmune inner ear disease (AIED), because it is thought that the hearing loss is...
What is the current status of trial NCT00000361?
This trial is currently terminated. It is a Phase 3 study. The study started on 1998-03. Estimated completion is 2002-11.
What interventions are being tested in trial NCT00000361?
The interventions under investigation include: Methotrexate (DRUG), Corticosteroids (DRUG).
Who is sponsoring clinical trial NCT00000361?
This trial is sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD), which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.